These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 16719908

  • 21. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC.
    Neurology; 2009 Feb 24; 72(8):705-11. PubMed ID: 19073945
    [Abstract] [Full Text] [Related]

  • 22. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.
    Smith ME, Stone LA, Albert PS, Frank JA, Martin R, Armstrong M, Maloni H, McFarlin DE, McFarland HF.
    Ann Neurol; 1993 May 24; 33(5):480-9. PubMed ID: 8498825
    [Abstract] [Full Text] [Related]

  • 23. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.
    Molyneux PD, Filippi M, Barkhof F, Gasperini C, Yousry TA, Truyen L, Lai HM, Rocca MA, Moseley IF, Miller DH.
    Ann Neurol; 1998 Mar 24; 43(3):332-9. PubMed ID: 9506550
    [Abstract] [Full Text] [Related]

  • 24. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
    Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL.
    Mult Scler; 2008 Jun 24; 14(5):663-70. PubMed ID: 18424479
    [Abstract] [Full Text] [Related]

  • 25. Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy.
    Schocke MF, Berger T, Felber SR, Wolf C, Deisenhammer F, Kremser C, Seppi K, Aichner FT.
    Neuroimage; 2003 Oct 24; 20(2):1253-63. PubMed ID: 14568494
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.
    Neurology; 2009 Jun 09; 72(23):1976-83. PubMed ID: 19279320
    [Abstract] [Full Text] [Related]

  • 27. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
    Sormani MP, Stubinski B, Cornelisse P, Rocak S, Li D, De Stefano N.
    Mult Scler; 2011 May 09; 17(5):541-9. PubMed ID: 21148262
    [Abstract] [Full Text] [Related]

  • 28. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
    Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.
    Neurology; 2001 Oct 09; 57(7):1239-47. PubMed ID: 11591843
    [Abstract] [Full Text] [Related]

  • 29. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT.
    Neurology; 2008 Oct 28; 71(18):1390-5. PubMed ID: 18525027
    [Abstract] [Full Text] [Related]

  • 30. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.
    Gauthier SA, Glanz BI, Mandel M, Tsagkaropoulos A, Neema M, Stankiewicz J, Arora A, Duan Y, Liptak Z, Egorova S, Buckle GJ, Bakshi R, Guttmann CR, Khoury SJ, Weiner HL.
    J Neurol Sci; 2009 Sep 15; 284(1-2):116-9. PubMed ID: 19428028
    [Abstract] [Full Text] [Related]

  • 31. Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses.
    Chapman C, Tubridy N, Cook MJ, Mitchell PJ, MacGregor LR, Lovelock C, Litewka L, Sedal L, Kilpatrick TJ, Butzkueven H.
    J Clin Neurosci; 2006 Jul 15; 13(6):636-8. PubMed ID: 16790352
    [Abstract] [Full Text] [Related]

  • 32. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
    Agosta F, Absinta M, Sormani MP, Ghezzi A, Bertolotto A, Montanari E, Comi G, Filippi M.
    Brain; 2007 Aug 15; 130(Pt 8):2211-9. PubMed ID: 17535835
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A randomized crossover study of bee sting therapy for multiple sclerosis.
    Wesselius T, Heersema DJ, Mostert JP, Heerings M, Admiraal-Behloul F, Talebian A, van Buchem MA, De Keyser J.
    Neurology; 2005 Dec 13; 65(11):1764-8. PubMed ID: 16221950
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K, PRIVIG Study Group, UBC MS/MRI Research Group.
    Neurology; 2008 Jul 22; 71(4):265-71. PubMed ID: 18645164
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.
    Cocco E, Marchi P, Sardu C, Russo P, Paolillo A, Mascia M, Solla M, Frau J, Lorefice L, Massole S, Floris G, Marrosu M.
    Mult Scler; 2007 Sep 22; 13(8):975-80. PubMed ID: 17468439
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.